Top 12 Drug Patents Expiring as early as February 2025
Several high-value drug patents are expiring as early as February 2025, along with their data exclusivities. The list includes Farxiga, Mounjaro, and Ozempic, opening a window for generic developers to strategically target high-value drugs. GreyB analyzed all the drug patents expiring between 2025 and 2040 and spotted the top 12 high-value drugs. The analysis highlights: […]
nChain’s Patent Portfolio Analysis
In 2023, nChain announced a partnership with Japan’s FinTeK (Keio University) to expedite the adoption of blockchain technology in the region. This collaboration showcases nChain’s strategy to broaden its influence in key markets while holding the most extensive patent portfolio in the blockchain sector. With approximately 695 patents as of September 2024, nChain has become […]
The Ofev Patent Thicket: Patents expiring in 2026
With an average life expectancy of 3-5 years after diagnosis, Pulmonary fibrosis highlights an urgent need for innovative therapeutic interventions. That’s where medications like Ofev have emerged as a transformative solution. Ofev is the trade name for Nintedanib by Boehringer Ingelheim. It is a Tyrosine Kinase Inhibitor (TKI) or anti-fibrotic agent used to treat non-small […]
The Trajenta Patent Thicket: Patents expiring in 2025
Trajenta, known for its effective glycemic control without weight gain, is a key player in the diabetes medication sector. This critical medication, known generically as Linagliptin, is on the brink of its patent expiration, presenting an opportunity for generic drug manufacturers to introduce their own generic versions. Manufactured by Boehringer Ingelheim, Trajenta® is an oral […]
Recent Patent Oppositions in the Pharmaceutical Industry
The European Patent Office (EPO) receives more than 2000 oppositions each year, directly impacting the future success and exclusivity of pharmaceutical products. Monitoring the outcomes of these oppositions is crucial as it assists in developing effective strategies for launching generic versions of drugs. Moreover, it aids in identifying competitors that may be eating into market […]
Understanding the Farxiga®/Forxiga® Patent Thicket: What’s Changing in 2025
While numerous drugs for diabetes are available in the market, many come with undesirable side effects such as weight gain, hypoglycemia, and hypertension. However, a game-changing solution has been introduced in the form of Farxiga®/Forxiga®. Farxiga®/Forxiga® is the trade name for Dapagliflozin, by AstraZeneca. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, representing a novel […]
Arthritis Drug Patents Expiring 2024 – 2028
The arthritis treatment industry is characterized by its intense competitiveness, driving companies to invest significantly in research and development to secure leading arthritis drug patents. Consequently, the expiration of patents for this disease creates significant opportunities for companies specializing in generic medications. A notable example of the market dynamics in this industry is the case […]
The Mounjaro Patent Thicket: Patents expiring in 2036
More than 500 million people around the world are affected by diabetes, and this issue is intensified by a surging obesity crisis, particularly in wealthier nations. In such a crisis, drugs like Mounjaro represent a highly lucrative opportunity for generic drugmakers to address the escalating medical demand on a global scale. For reference, here is […]
Cancer Drug Patents Expiring 2024-2028
The fiercely competitive nature of the oncology industry makes the companies invest heavily in research and development to bring in top cancer-treating drug patents. Consequently, the expiration of patents for cancer drugs creates significant opportunities for companies specializing in generic medications. Identifying these patents can help enterprises expand and diversify their generic drug portfolios. This […]
30 Diabetes Drug Patents Expiring from 2024 till 2028 – GreyB
Given the competitive nature of the pharmaceutical domain, the expiration of drug patents presents significant opportunities, particularly for companies specializing in generic medications. Pharmaceutical companies seeking to expand or diversify their generic drug portfolios would find this list of great value in identifying diabetes drug patents that will expire between 2024 and 2028. By utilizing […]
Patent Family Tree: A Visual Guide to Understanding Patent Portfolios
A patent family is an unparalleled fortress, strategically safeguarding intellectual property across multiple jurisdictions. It forms a robust defense, enabling swift and global protection against unauthorized use of innovative concepts. However, understanding global patent portfolios is complex and exhaustive. Navigating these connections across borders becomes challenging. Imagine simplifying this process with a visual map that […]
Perform Competitor Research In 30 Seconds – GreyB’ CompInsight
Have you considered that by solely performing competitor research based on their online presence and ranking, you miss many innovative companies working on similar technologies? These companies may have even patented their innovations, which makes them the REAL COMPETITORS to your business. After all, patent data reveals innovators entering your domain at an early stage- […]
Does the FDA’s warning mark an end to Ozempic?
The recent FDA controversy around Novo Nordisk’s Ozempic has brought many eyes to the drug. For the uninitiated, Ozempic (semaglutide) is an anti-obesity medication for long-term weight management. However, an FDA-approved label was recently updated to warn of potential serious intestinal side effects like obstruction or blockage. In this study, we see how this FDA […]
Lead the generic drug market with this one effective strategy
Closely monitoring the patent expirations of well-known branded drugs, such as Abilify for schizophrenia and Abaraxane for cancer treatment, is essential. This practice of monitoring patents can give generic drug makers a significant competitive edge, ultimately granting them an advantage in the generic drug market. As top blockbuster drugs approach patent expiration, strategic ANDA filings […]
15 Critical Factors Before Purchasing a Patent Portfolio
If patents are your bread and butter, you know as much as I do that a thorough patent portfolio analysis is critical before deciding to buy them. However, the situation gets complicated by thousands of patents in the portfolio. It begs the question: Should I hire specialists to conduct a thorough examination? Is it worth […]
Tap Into The Loteprednol Etabonate Generic Drug’s Transformational Potential
In 2020, the FDA approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis, Kala Pharmaceuticals Inc.) for treating dry eye disease. As one of the most common ocular surface disorders, dry eye disease impacts 16.7 million to 50.2 million people in the U.S.A. Additionally, this disease costs over $55.4 billion to the economy each year. Eysuvis ophthalmic […]
